Thalidomide is an important advance in the treatment of multiple myeloma. In Japan thalidomide is now on the approval step for the treatment of multiple myeloma. The drug has some bothersome side eŠects such as defect of organogenesis, neuropathy, constipation and fatigue, but is likely more eŠective than standard chemotherapy and is changing multiple myeloma treatment. At this moment, Japanese patients must import the thalidomide preparations from Mexico, Britain and elsewhere, but after approval, they patients will be able to get the new Japanese thalidomide capsules. In order to determine appropriate amounts of Japanese thalidomide capsules in the treatment of multiple myeloma, we compared the dissolution proˆle and plasma thalidomide concentrations of Japanese and British capsules and Mexican tablets. The dissolution test was performed according to the Japanese and the United States Pharmacopoeia. The pharmacokinetic data for Japanese capsules were obtained from the clinical trial in Japanese subjects and compared with those data published for other formulations. The dissolution rate of the Japanese capsule was the fastest, followed by British and Mexican formulations. The pharmacokinetic proˆles of Japanese and British capsules were similar, while the 100 mg Japanese thalidomide capsule demonstrated a 1.6-fold higher maximum plasma concentration than the 200 mg Mexican thalidomide tablet (1.7 vs. 1.1 mg/ml), greatly shortened t max (4.5 vs. 6.2 h), and the apparent half life was only one-third of the Mexican tablet (4.8 vs. 13.5 h). A comparison of the dissolution and the pharmacokinetic absorption proˆles demonstrated a rank-order correlation. Physicians and pharmacists should be aware of the probable alteration in plasma thalidomide concentration when switching to the Japanese capsule, especially from the Mexican tablet, and should monitor clinical response carefully.
120 分後の溶出液中のサリドマイド濃度を HPLC Cmax：maximum concentration, tmax：time to maximum concentration, AUC0-∞：area under concentration time proˆle to time inˆnity, t1/2：ap-parent elimination half-life, MRT：mean residence time. The pharmacokinetic parameters of MEX determined by non-compartment analysis were obtained from previous reports. 5) The non-compartmental pharmacokinetic parameters of IV and UK were calculated from the compartmental parameters in previous reports. 4, 6) Values are mean±S.D. 
